Operating with a legacy spanning more than 70 years, Nobel İlaç has executed a strategic turnaround in its corporate framework to increase market agility and capture emerging healthcare trends. The manufacturer has segmented its domestic sales and marketing functions to elevate operational productivity and strengthen its penetration into niche therapeutic fields.
Under the new corporate mapping, the "Exclusive Products" and "Longevity" departments—designed to address forward-looking healthcare vectors and healthy aging matrices—have been scaled to full directorate status. Promoting executives who have spent a major portion of their professional careers within Nobel İlaç to these critical oversight roles underscores the brand's commitment to retaining institutional memory and sustaining an internal promotion-led leadership culture.
Organizational Architecture and Executive Appointments
Following the reconfiguration of the Sales and Marketing matrix, the senior leadership assignments and structural updates are outlined below:
Core Products Directorate: Bahri Karayaka, formerly serving as Cardiology 2 Department Manager, has been appointed as Director.
Specialty Products Directorate: Ali Engin, who managed operations as Cardiology 1 Department Manager, steps in as Director.
Exclusive Products Directorate: Kemal Özkan, previously the Department Manager for Hepatology, Nephrology, and Rare Diseases 2, has been named Director of this newly configured division.
Nobel Longevity Directorate: Özer Sinan Yalanuz, who held the position of Nobel Longevity Department Manager, has been promoted to Director of this forward-looking unit.
Central Nervous System (CNS) Marketing Management: Duygu Değirmencioğlu has been appointed as the new Marketing Manager for the segment.
Company officials noted that this updated departmental model aims to consolidate market share across the existing pharmaceutical portfolio while establishing a sustainable growth index within innovative segments such as chronic treatments, rare diseases, and preventative medicine lines.
